Oragenics Shares Are Trading Higher After the Company Provided a Corporate Update on Its 2024 Progress Including Developments of ONP-002, Its Lead Candidate for Concussions.
Oragenics Shares Are Trading Higher After the Company Provided a Corporate Update on Its 2024 Progress Including Developments of ONP-002, Its Lead Candidate for Concussions.
oragenics股票交易有所上升，公司發佈了有關2024年進展的企業更新，包括其顱腦震盪主力候選藥物ONP-002的進展。
Oragenics Shares Are Trading Higher After the Company Provided a Corporate Update on Its 2024 Progress Including Developments of ONP-002, Its Lead Candidate for Concussions.
oragenics股票交易有所上升，公司發佈了有關2024年進展的企業更新，包括其顱腦震盪主力候選藥物ONP-002的進展。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間